APA (7th ed.) Citation

Borchmann, P., Moccia, A. A., Greil, R., Schneider, G., Hertzberg, M., Schaub, V., . . . Giri, P. (2023). BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL. Hematological oncology, 41, 881. https://doi.org/10.1002/hon.3196_LBA5

Chicago Style (17th ed.) Citation

Borchmann, P., et al. "BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL." Hematological Oncology 41 (2023): 881. https://doi.org/10.1002/hon.3196_LBA5.

MLA (9th ed.) Citation

Borchmann, P., et al. "BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL." Hematological Oncology, vol. 41, 2023, p. 881, https://doi.org/10.1002/hon.3196_LBA5.